Conference Track

Antiretroviral Resistance, Treatment Interruptions, & Salvage Therapy

Source: CCO Independent Conference Coverage of the 2003 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Expert Analysis

Antiretroviral Resistance, Treatment Interruptions, & Salvage Therapy

Program Director: John P. Phair, MD

Faculty:

Joel E. Gallant, MD, MPH
William A. O'Brien, MD, MS
Andrew R. Zolopa, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss data on the effects of discontinuing agents comprising only part of a treatment regimen
Outline the likely role of T-20 and atazanavir in treatment strategies
Describe recent research on the possible role of treatment interruptions in patient management

Earn CME credit by reading the expert analysis and commentary on the antiretroviral management of patients receiving therapy. Topics covered include:

Treatment interruption and resumption based on CD4+ cell count
Intermittent therapy
Treatment interruption before starting salvage therapy
Partial treatment interruptions
T-20 as a component of salvage therapy
Implications of atazanavir's resistance profile
Resistance testing

CREDIT INFORMATION

Release Date: March 06, 2003

Expiration Date: March 05, 2004

Physicians: maximum of 2.0 AMA PRA Category 1 Credits™

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.